Skip to content
RecallWatchMedical Device Safety
Class IIOngoingZ-1784-2025

Beckman Coulter Inc. recalls DxC 500 AU Clinical Chemistry Analyzer

Beckman Coulter Inc.Brea, CA, United StatesReported May 21, 2025 · 1 year ago
Legal News Analyst ·

Reason for recall

Beckman Coulter is recalling their DxC 500 AU Clinical Chemistry Analyzer because a software error causes the analyzer to not run a requested calibration order in the following scenario: when a reagent blank or calibration is ordered during sample processing and then any of the components (R1 and/or R2) depletes to zero tests, the analyzer will not be able to complete the calibration request, and the calibration order will remain pending. No further calibration orders can be processed for any assays, and the instrument refuses to accept further sample processing order after the existing calibration curves are expired. Although in-process tests will be completed, this error can cause a delay in reporting subsequent test results. No further calibration orders can be processed for any assays which may cause a delay in reporting test results.

Affected product

Check your device

Enter a lot, serial, REF, or UDI number from your device's label to check it against this recall's listed codes.

Affected products & lots

  • DxC 500 AU Clinical Chemistry Analyzer, Catalog Numbers/UDI codes: C63519 / 14987666545058 C63520 / 14987666545065. The Beckman Coulter DxC 500 AU Clinical Chemistry Analyzer is an automated chemistry analyzer that measures analytes in samples, in combination with appropriate reagents, calibrators, quality control (QC) material and other accessories. This system is for in vitro diagnostic use only
    UDI-DI codeCatalog # Number
    2 affected lots
    C6352014987666545065

What the firm is doing

On or about 03/20/2025, the firm sent via email or postal mail an Urgent Medical Device Recall letters informing customers that Beckman Coulter has determined that the DxC 500 AU Clinical Chemistry Analyzer may not run a requested calibration order for a two-part reagent and subsequently prevents any new calibration order from being placed. For two-part reagents, when reagent blank or calibration is ordered during sample processing and then any of the components (R1 and/or R2) depletes to zero tests, the analyzer will not be able to complete the calibration request, and the calibration order will remain pending. The analyzer will not allow additional calibration orders to be requested for any assays. Customers are instructed to: . Do not place calibration orders when the analyzer is processing samples. . Refer to the DxC 500 AU IFU Reagent Overview section for instructions on Monitoring the Status of Reagents. . Beckman Coulter recommends sharing the content of this letter with their laboratory and/or Medical Director. . If they experience this issue on software version 1.3, 1.4, 1.4.1 or 1.4.2, contact Beckman Coulter for service. . Beckman Coulter recommends posting this Recall Letter on or near the affected systems until the corrections have been made. Resolution: . This has been resolved in software version 1.4.3 in December of 2024. . Your Beckman Coulter service representative will contact you to schedule the software upgrade. For questions - contact Customer Support Center at: . From our website: http://www.beckmancoulter.com . Troubleshooting Hotline: (800) 854-3633

DistributionShow details

U.S: AL, CA, GA, ID, IN, LA, MA, MI, MN, MT, NC, NV, PA, PR, TN , TX, and WI O.U.S.: Australia, Belgium, Bosnia and Herzegovina, Canada, Chile, Croatia, Egypt, Ethiopia, France, Germany, Ghana, India, Italy, Korea, Lebanon, Libya, Malaysia, Netherlands, North Macedonia, Oman, Paraguay, Philippines, Poland, Puerto Rico, Qatar, Saudi Arabia, South Africa, Spain, Switzerland, and Tunisia

Class IIWhat this means

Use of the product may cause temporary or medically reversible adverse health consequences.

Sources & references

Taylor Coteus
Legal News Analyst

Taylor Coteus is RecallWatch's Legal News Analyst, covering FDA medical-device enforcement and patient-safety litigation. He reviews every recall against the FDA's official openFDA record before it is published and is responsible for corrections and editorial accuracy.

More Class II recalls